Brief: Suven Life Sciences Ltd Receives EIR From U.S. FDA For Pashamylaram Facility
Dec 19 (Reuters) - Suven Life Sciences Ltd SUVP.NS :
* SUVEN LIFE SCIENCES LTD SAYS RECEIVES EIR FROM US FDA FOR
ITS
PASHAMYLARAM FACILITY
* SUVEN LIFE SCIENCES LTD SAYS FDA HAS DETERMINED THAT
INSPECTION
CLASSIFICATION OF THIS FACILITY IS "VOLUNTARY ACTION INDICATED"
Source text for Eikon: ID:nBSE9ZhWMp
Further company coverage: SUVP.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees